Prostate cancer ye nye kansa evelia si bɔ wu le ŋutsuwo dome le xexeame katã, eye wobu akɔnta be ame 1,276 ye xɔe le ƒe 2018 me, si nye kansa siwo katã le ŋutsuwo me ƒe 7.1%
Dɔdzẽ si wua ame hã sɔ gbɔ ŋutɔ, eye wobu akɔnta be ame 37,005 ye ku le xexea me godoo le ƒe 2018 me.
Gake amesiwo kuna le dɔ sia ta ƒe xexlẽme toa vovo le nuto vovovowo me, eye Ɣetoɖoƒe Afrika ye xɔ nɔƒe atɔ̃lia le xexeame katã le amesiwo kuna le dɔ sia ta ƒe xexlẽme gome, eye Nigeria ye nye dukɔ si me amewo sɔ gbɔ le wu le nuto sia me eye eƒe ganyawo hã de ŋgɔ wu.
Le Nigeria la, tsinyegoe me kansae nye kansa si bɔ wu eye wòwua ŋutsuwo wu, eye wobu akɔnta be ŋutsu 32,8 ye xɔa dɔ sia eye 16,3 kuna le ŋutsu 100,000 ɖesiaɖe me.
Esia sɔ gbɔ wu amesiwo kuna le Dziehe Amerika ƒe teƒe eve.
Dɔlélea kpɔkpɔ kaba, nusiwo hiã hena edodo kpɔ kple edede dzesi, kple nuŋlɔɖi kple nyatakaka siwo ku ɖe eŋu ƒe anyimanɔmanɔ hã na be amewo kuna le Nigeria.
Le United States la, tsinyegoe me kansae nye kansa si wua ŋutsuwo wu le nu bubu ɖesiaɖe me, eye ŋutsu siwo ade 40,000 kuna ƒe sia ƒe.
Tsinyegoe me kansa ƒe amewuwu dzi le ɖeɖem kpɔtɔ tso ƒe 1990 ƒeawo me, gake egakpɔtɔ nye lãmesẽkuxi gã aɖe.
Le goawo katã me la, tsinyegoe me kansa nye dɔléle si wua ame, vevietɔ le nuto siwo me womekpɔa atikewɔwɔ kple dɔdamɔnu siwo ana woadae akpɔ o la me.
Gake enyanya kaba kple atikewɔwɔ ate ŋu ana woahaya kaba eye wòana ame naku.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Mɔxeɖenu: atikewɔwɔ']
['Taɖodzinu siwo nye nufiafia kple nyatakaka koe le nyatakakadzraɖoƒe sia ŋu eye menye atikewɔwɔ ŋuti ɖaŋuɖoɖo alo dɔwɔnawo ƒe nya gblɔm wole o.']
['Mele be woazã nyatakaka siwo wona la atsɔ ada dɔléle alo dɔ aɖe o, eye ele be amesiwo di be yewoakpɔ atikewɔwɔ ŋuti ɖaŋuɖoɖo na yewo la nabia ɖɔkta si xɔ mɔɖegbalẽ.']
['De dzesii be neural network si wɔa nyabiabiawo ƒe ŋuɖoɖowo la meɖia o vevietɔ ne wotsɔ xexlẽdzesiwo wɔe. Le kpɔɖeŋu me, ne wotsɔ ame siwo ŋu dɔléle aɖe le ƒe xexlẽme wɔ dɔe.']
['Bia wò ɖɔkta alo lãmesẽdɔwɔla bubu si dze ƒe aɖaŋuɖoɖo ɣesiaɣi le lãmesẽkuxi aɖe ŋu. Mègaŋe aɖaba ƒu aɖaŋuɖoɖo si ɖɔktawo ɖo na wò alo gbɔ dzi ɖi le exexlẽ me le nyatakakadzraɖoƒe sia ta o. Ne èsusu be ɖewohĩ lãmesẽkuxi aɖe le fu ɖem na ye la, ke yɔ 911 alo yi ɖe afisi wokpɔa nɔnɔme kpatawo gbɔ le.']
['Copyright: Copyright']
['Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) na mɔ siwo dzi copyright ƒe nunɔlawo ate ŋu ato awɔ nu ɖe nu siwo wo xɔ se be wo le Internet dzi la ŋu.']
['Ne èxɔe se kple kakaɖedzi be nyatakakadzraɖoƒe alo dɔwɔnu aɖe si míetsɔ wɔ míaƒe nyatakakadzraɖoƒea alo dɔwɔnawo la nye dada le wò gome la, wò ŋutɔ (alo wò dɔtɔ) ate ŋu aŋlɔ agbalẽ aɖo ɖe mí abia be míaɖe nyatakakadzraɖoƒea alo dɔwɔnua ɖa alo axe mɔ ɖe ezazã nu.']
['Ele be woana nyatakakawo to e-mail dzi (kpɔ "Kpekpeɖeŋunaƒe" ƒe akpa si nye e-mail adrɛs). ']
['DMCA bia be nàŋlɔ nyatakaka siwo gbɔna ɖe wò nyatakaka si nèŋlɔ be woada le copyright dzi la me: (1) nuŋɔŋlɔ si fia be copyright le dɔ si ŋu wole nu ƒom le la ŋu; (2) nyatakaka si fia be nuŋɔŋlɔa le eme eye wòade mía nu be míake ɖe eŋu; (3) nyatakaka siwo ana míake ɖe ŋuwò, siwo dometɔ aɖewoe nye wò adrɛs, kaƒodzesi kple e-mail adrɛs; (4) wò nya si fia be èxɔe se kple kakaɖedzi be copyright ƒe ame si tɔe nyatakakaa nye, alo eƒe dɔtɔ, alo se aɖeke meɖe mɔ ɖe eŋu o; ']
['(5) Wò ŋutɔ nàŋlɔ agbalẽ si dzi nàde asii, si me nàde se be ne mèwɔe o la, àda alakpa, atsɔ aɖo kpe edzi be nyatakaka siwo le nyatakakaa me la de pɛpɛpɛ eye be ŋusẽ le asiwò be nàʋli agbalẽ siwo ŋu wogblɔ le be woda le la ta.']
['Eye (6) ame si tɔe agbalẽa nye alo ame si wona ŋusẽe be wòawɔ dɔ le ame si tɔ ŋkɔ me la ƒe asinuŋɔŋlɔ alo eƒe asinuŋɔŋlɔ si le mɔ̃ dzi. ']
['Ne mèŋlɔ nyatakaka siwo katã le etame ɖe agbalẽa me o la, ate ŋu ana be wò nyatoƒoe me dzodzro natsi megbe.']
['Kadodo']
['Taflatse ɖo email ɖe mí ne nyabiabia alo aɖaŋuɖoɖo aɖe le asiwò.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Le Eŋu']
['BioMedLib zãa kɔmpiuta siwo wɔa dɔ le wo ɖokui si (mɔ̃ siwo zãa mɔ̃ɖaŋunuwo tsɔ srɔ̃a nu) tsɔ wɔa nyabiabia kple ŋuɖoɖowo.']
